By: Allen Wilbanks
Date: September 28, 2023
Raajit Rampal MD. PhD, offered a glimpse of what the audience could expect. He mentioned, “We’ll have Rajith talking about Jack one, whether inhibiting it is a good thing or not so much, and what exactly it means in our patients.” He then introduced Steve O, who would delve into Nf Kappa b and present his much-talked-about ACVR research from the last ASH meeting.
Rampal introduced the esteemed speakers, acknowledging Steve O from Washu and himself, Raajit Ramal from Stone Kettering. With a playful tone, he acknowledged the potential for missteps, saying, “So the only way we’re going to mess this up is if I say something stupid.”
Raajit Ramal continued to engage the audience, emphasizing the symposium’s scientific nature, stating, “So again, welcome to what promises to be a truly fascinating session, and now, I’m excited to invite Raji to kick it off with his insights on Jack.”
Rampal began his presentation with a touch of humor, renaming his topic, saying, “Alright, it’s fantastic to be here with all of you. The title of my talk is all about ‘loosening the role of Jack’ when it comes to normal hematopoiesis, immune function, and other aspects. I’ve taken some artistic liberty; let’s call it ‘Jacqueline Innovation.’ Is it good for something? Absolutely, something. We’ll delve into that.”
He proceeded to provide a thorough overview of JAK inhibitors, highlighting their differences and potential impact on both efficacy and toxicity. Raajit Ramal explained the biochemical aspects of various JAK inhibitors, such as ruxolitinib, fedratinib, acritinib, and Momelotinib.